| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/25/2003 | US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants |
| 09/25/2003 | US20030181455 Bicyclic and tricyclic hetroaromatic compounds |
| 09/25/2003 | US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate |
| 09/25/2003 | US20030181446 Novel N-acylated heterocycles |
| 09/25/2003 | US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents |
| 09/25/2003 | US20030181439 Use of paullone derivatives for making medicines |
| 09/25/2003 | US20030181422 Cardioprotective phosphonates and malonates |
| 09/25/2003 | US20030181420 Modulators of LXR |
| 09/25/2003 | US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer |
| 09/25/2003 | US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof |
| 09/25/2003 | US20030181394 Carbobydrates such as alpha-D-galactopyranosyl-1,2-glycerol and/or isomers, obtained by solvent extraction from algae, for use as viricides or anticarcinogenic agents |
| 09/25/2003 | US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery |
| 09/25/2003 | US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 09/25/2003 | US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire |
| 09/25/2003 | US20030181381 Factor X analogues having a modified protease cleavage site |
| 09/25/2003 | US20030181376 Control of crop pests & animal parasites through direct neuronal uptake |
| 09/25/2003 | US20030181370 H-Y antigen |
| 09/25/2003 | US20030181363 Compounds or pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease. |
| 09/25/2003 | US20030181362 Receptor |
| 09/25/2003 | US20030181360 Human TSLP DNA and polypeptides |
| 09/25/2003 | US20030181359 Tripeptide prodrug compounds |
| 09/25/2003 | US20030181352 Substituted heterocyclic compounds |
| 09/25/2003 | US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 09/25/2003 | US20030180893 Biotransformation of biologically active compounds made of various classes of chemical substance by means of laccase and manganese peroxidase enzymes |
| 09/25/2003 | US20030180887 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 09/25/2003 | US20030180818 Isolated nucleic acid molecules encoding human peptidoglycan recognition protein-related proteins, referred to PGRP-K (keratinocytes), PGRP-W (wound healing) and PGRP-C (chondrosarcoma) |
| 09/25/2003 | US20030180813 Method of screening remedy for diabetes |
| 09/25/2003 | US20030180805 Methods and compositions for derepression of IAP-inhibited caspase |
| 09/25/2003 | US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3 |
| 09/25/2003 | US20030180752 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/25/2003 | US20030180744 High affinity oligonucleotide ligands to growth factors |
| 09/25/2003 | US20030180739 Culturing a cell in the presence or absence of the compound, assaying the cell for expression or activity of gene(s), detecting the compound when expression of the genes is lower in the presence of the compound than in the absence |
| 09/25/2003 | US20030180734 Peptide nucleic acids |
| 09/25/2003 | US20030180712 Host cells transfected with a recombinant expression vector containing nucleic acid control sequences operatively linked to an L-type Ca2+ channel beta 3 gene; host cell free of functional beta 3 subunit-containing L-type Ca2+ channels |
| 09/25/2003 | US20030180405 For cosmstics, drugs; antiinflamamtory agents; oxidation resistance |
| 09/25/2003 | US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
| 09/25/2003 | US20030180396 Central nervous system disorders; screening for allergens |
| 09/25/2003 | US20030180386 Aqueous metal bicarbonate solution and method of use |
| 09/25/2003 | US20030180383 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 09/25/2003 | US20030180364 Catheter injectable depot compositions and uses thereof |
| 09/25/2003 | US20030180362 Multi-stage oral drug controlled-release system |
| 09/25/2003 | US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet |
| 09/25/2003 | US20030180331 Facilitation of wound healing with CM101/GBS toxin |
| 09/25/2003 | US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation |
| 09/25/2003 | US20030180296 Antibodies that immunospecifically bind to trail receptors |
| 09/25/2003 | US20030180295 Angiocidin: a Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor |
| 09/25/2003 | US20030180294 Administering vascular endothelial growth factor receptor inhibitor; supression lymphangiogenesis |
| 09/25/2003 | US20030180285 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti hsp90 antibodies |
| 09/25/2003 | US20030180275 Human serpin polypeptides |
| 09/25/2003 | US20030180260 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor |
| 09/25/2003 | US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 09/25/2003 | US20030180237 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances |
| 09/25/2003 | US20030180236 Resorcinol derivatives |
| 09/25/2003 | US20030180231 Cosmetics, skin disorders; sunscreen agents; aging resistance |
| 09/25/2003 | DE10214095C1 Producing dedifferentiated, programmable stem cells of human monocytic origin using culture medium having M-CSF and IL-3, useful in treating cirrhosis, pancreatic insufficiency, kidney failure, cardiac infarction and stroke |
| 09/25/2003 | CA2479620A1 Ethane-1,2-diamino-bis[2r)-2-bromo-3-phenylpropanoate], method for production and use thereof |
| 09/25/2003 | CA2479352A1 Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient |
| 09/25/2003 | CA2479266A1 Azetidine derivatives as ccr-3 receptor antagonists |
| 09/25/2003 | CA2479222A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| 09/25/2003 | CA2479212A1 Central airway administration for systemic delivery of therapeutics |
| 09/25/2003 | CA2479153A1 Hybrid and single chain meganucleases and use thereof |
| 09/25/2003 | CA2479151A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain |
| 09/25/2003 | CA2479141A1 Pyridone derivatives |
| 09/25/2003 | CA2478808A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders |
| 09/25/2003 | CA2478805A1 Controlling chemical reactions by spectral chemistry and spectral conditioning |
| 09/25/2003 | CA2478803A1 Methods of modulating cd200 receptors |
| 09/25/2003 | CA2478795A1 Use of rapamycin for inhibiting cell death |
| 09/25/2003 | CA2478766A1 Polymer composition loaded with cells |
| 09/25/2003 | CA2478760A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states |
| 09/25/2003 | CA2478758A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 09/25/2003 | CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| 09/25/2003 | CA2478653A1 Methods of treatment with selective ep4 receptor agonists |
| 09/25/2003 | CA2478540A1 Indazoles substituted with an anti-cancerous activity |
| 09/25/2003 | CA2478500A1 Crystalline parecoxib sodium |
| 09/25/2003 | CA2478336A1 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| 09/25/2003 | CA2478310A1 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors |
| 09/25/2003 | CA2478211A1 Nk1 antagonists |
| 09/25/2003 | CA2478194A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy |
| 09/25/2003 | CA2478165A1 Sulfatase inhibiting progestogen-only contraceptive regimens |
| 09/25/2003 | CA2477832A1 Methods of treating diabetes using pde 11a inhibitors |
| 09/25/2003 | CA2477732A1 Aminomethyl-substituted thiazolobenzimidazole derivatives |
| 09/25/2003 | CA2476746A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs |
| 09/24/2003 | EP1346994A1 Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds |
| 09/24/2003 | EP1346731A1 Conjugates for treating inflammatory disorders and associated tissue damage |
| 09/24/2003 | EP1346730A1 Pretargeting methods and novel pretargeting conjugates |
| 09/24/2003 | EP1346728A1 Ophthalmological preparations |
| 09/24/2003 | EP1346065A2 Antisense modulation of src-2 expression |
| 09/24/2003 | EP1346061A2 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 09/24/2003 | EP1346058A2 Adenoviral systems and the uses thereof |
| 09/24/2003 | EP1346056A1 Methods for the production of multimeric proteins, and related compositions |
| 09/24/2003 | EP1346055A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 09/24/2003 | EP1346053A2 Polynucleotides encoding human phosphatases |
| 09/24/2003 | EP1346051A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 09/24/2003 | EP1346039A1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 09/24/2003 | EP1346033A2 Novel serine protease genes related to dppiv |
| 09/24/2003 | EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 09/24/2003 | EP1345979A2 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 09/24/2003 | EP1345968A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/24/2003 | EP1345963A2 Isolation of purified tgf- 1 and tgf- 2 from bone tissue |
| 09/24/2003 | EP1345957A2 Inhibitors of the e2f-1/cyclin interaction for cancer therapy |